Clinical Trial Update: Efficacy and Safety Study of Genetically Targeted Enzyme Replacement Therapy for Advanced Heart Failure [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial assessing a genetically targeted enzyme replacement therapy for advanced heart failure has completed, with results posted in 2014.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Dilated Cardiomyopathy
• Heart Failure

Drugs mentioned

• Genetically Targeted Enzyme Replacement Therapy

Snippet

Sponsor: Celladon Corporation | Conditions: Heart Failure, Congestive, Dilated Cardiomyopathy | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2014-08-20